News

Number of news items returned: 61 to 80 records of 404

"The Tooth Booth Business Model Delivers A Much Better GP Margin Percentage"

30 August 2017

(4473 views)

  "The Tooth Booth Business Model Delivers A Much Better GP Margin Percentage   The Tooth Booth Board is pleased to announce that ...

CXi Announces Second Client for Unit Registry

29 August 2017

(4471 views)

   CXi Announces Second Client for Unit Registry   "CXi Software (“CXi”) has announced that it has successfully migrated its second client, in ...

Invest in the first Chinese pharmaceutical company to list on the ASX: Haixi

22 August 2017

(5406 views)

  Invest in the first Chinese pharmaceutical company to list on the ASX: Haixi Pharmaceutical International Holdings Limited ASX: HXP   Dear Readers, I invite ...

Lobster, Diabetes, Dental and Unit Registries - Funding Strategies Connect July 2017

27 July 2017

(4906 views)

  Lobster, Diabetes, Dental and Unit Registries - Funding Strategies Connect July 2017   Dear Readers, Its been an exciting and interesting month since ...

Podcast: Filling the Gap in the Market (ft. Darren Berry from The Tooth Booth)

26 July 2017

(4936 views)

  Podcast: Filling the Gap in the Market (ft. Darren Berry from The Tooth Booth)   "Summary In this episode of Eden Exchanges we ...

CXi - "The Xero of unit registries" - signs first client

26 July 2017

(5018 views)

  CXi - "The Xero of unit registries" - signs first client      "New Australian fintech CXi Software Pty Ltd (CXi) announces that ...

Tooth Booth: Exceeds Forecast | In Negotiations with Coomera

25 July 2017

(4863 views)

  Tooth Booth: Exceeds Forecast | In Negotiations with Coomera   "The Tooth Booth Board are pleased to announce that the forecasted figures ...

Opmantek Announces San Francisco Corporate Headquarters

20 July 2017

(5120 views)

    Opmantek Announces San Francisco Corporate Headquarters   "Opmantek are set to increase their foothold on the US market with the establishment of ...

Director Briefing with Darren Berry - The Tooth Booth Limited

28 June 2017

(6878 views)

  Please read the full briefing via the link below. For more information about The Tooth Booth Limited, please click here.  

EOFY Opportunities & Updates - Funding Strategies Connect June 2017

20 June 2017

(6814 views)

  EOFY Opportunities & Updates - Funding Strategies Connect June 2017   Dear Readers, The end of the financial year is fast approaching and ...

Tooth Booth Appoints Board Members

19 June 2017

(7292 views)

  "Tooth Booth Appoints Board Members"   "Tooth Booth’s Managing Director, Darren Berry, is pleased to announce that the Company has appointed Debra Burden ...

"The Tooth Booth to undertake capital raises ahead of longer-term IPO - owner"

16 June 2017

(6963 views)

"The Tooth Booth to undertake capital raises ahead of longer-term IPO - owner"   "The Tooth Booth, an unlisted public Australian dental ...

CXi delivers Seed Clients into Beta and increases Development Team

16 June 2017

(6662 views)

  "CXi delivers Seed Clients into Beta and increases Development Team"   "CXi software is pleased to announce it has migrated two of ...

"Time to replace that bucket" says Trustee Tailored Super

10 June 2017

(7173 views)

  "Time to replace that bucket" says Trustee Tailored Super   "We continue to highlight, that without Smart Defaults like TTS, in 2050 ...

The Tech Corner: BioCube

31 May 2017

(8276 views)

  "The Tech Corner: BioCube A shipping container that processes waste and plant materials into green energy that can run engines and ...

Tractile shades Tesla

25 May 2017

(9163 views)

  "Tractile leaves Tesla solar roof tiles in the shade   Renowned global entrepreneur Elon Musk’s latest product offering, solar roof tiles, are ...

Tooth Booth, CXi Software, News and Events - Funding Strategies Connect May 2017

19 May 2017

(8870 views)

  Tooth Booth, CXi Software, News and Events - Funding Strategies Connect May 2017 Dear Reader, Welcome back for the May edition of ...

Tooth Booth Westfield North Lakes to open August 2017

18 May 2017

(8989 views)

    "Tooth Booth Westfield North Lakes to open August 2017   Tooth Booth are in final discussions with Westfield North Lakes to open ...

Merger Brings Global Financial Network to Melbourne

05 May 2017

(9854 views)

  Merger Brings Global Financial Network to Melbourne    Fast growing capital markets group BlueMount Capital has welcomed Melbourne-based corporate advisory and investment ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625